Antibacterial Pipeline Hampered By Emerging Resistance From Pharma
Executive Summary
Pharma companies may need to place increased emphasis on discovery and development of novel anti-infective agents in order to address the proliferation of multidrug-resistant gram-negative infections
You may also be interested in...
Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA
Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)
Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA
Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)
GSK Trades In Anti-Infective R&D Model, Starts CEDD For Infectious Disease
GlaxoSmithKline is increasing its focus on anti-infective R&D with the creation of a Center of Excellence for Drug Discovery devoted to infectious diseases